PNPLA3 polymorphism increases risk for and severity of chronic hepatitis C liver disease

Habeeb Salameh, Maen Masadeh, Muhannad Al Hanayneh, Vincent Petros, Matthew Maslonka, Arjun Nanda, Ashwani K. Singal

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

AIM To examine the association of PNPLA3 polymorphisms in chronic hepatitis C patients and development of liver disease spectrum. METHODS Literature was searched systematically from PubMed/MEDLINE, EMBASE, and Cochrane search engines for full-length articles written in English that examined PNPLA3 polymorphism in chronic hepatitis C (CHC) patients. Studies evaluating the association of PNPLA3 polymorphism spectrum (fatty liver, steatohepatitis, cirrhosis, and hepatocellular carcinoma) of CHC were included. Pooled data are reported as OR with 95%CI. Our study endpoint was the risk of the entire liver disease spectrum including: Steatosis/fatty liver, cirrhosis, and hepatocellular carcinoma in CHC patients with PNPLA3 polymorphisms. RESULTS Of 380 studies identified, a total of 53 studies were included for full-text review. Nineteen on chronic hepatitis C were eligible for analysis. Pooled ORs for rs738409 GG compared to CC and CG among patients with fatty liver was 2.214 (95%CI: 1.719-2.853). ORs among advanced fibrosis/cirrhosis were 1.762 (95%CI: 1.258-2.468). Similar odds ratios among hepatocellular carcinoma patients were 2.002 (95%CI: 1.519-2.639). Pooled ORs for rs738409 GG and CG compared to CC among patients with fatty liver were 1.750 (95%CI: 1.542-1.986). Pooled ORs for advanced fibrosis/cirrhosis patients were 1.613 (95%CI: 1.211-2.147). All analyses were homogenous and without publication bias except one. The associations were maintained after adjusting for publication bias and heterogeneity. CONCLUSION PNPLA3 polymorphisms have strong association with increased risk and severity of the liver disease spectrum in CHC patients.

Original languageEnglish (US)
Pages (from-to)1584-1592
Number of pages9
JournalWorld Journal of Hepatology
Volume8
Issue number35
DOIs
StatePublished - 2016

Fingerprint

Chronic Hepatitis C
Liver Diseases
Fatty Liver
Fibrosis
Hepatocellular Carcinoma
Publication Bias
Liver Cirrhosis
Search Engine
PubMed
MEDLINE
Odds Ratio

Keywords

  • Cirrhosis
  • Hepatitis C virus
  • Hepatocellular carcinoma
  • PNPLA3 polymorphism
  • Rs738409

ASJC Scopus subject areas

  • Hepatology

Cite this

PNPLA3 polymorphism increases risk for and severity of chronic hepatitis C liver disease. / Salameh, Habeeb; Masadeh, Maen; Al Hanayneh, Muhannad; Petros, Vincent; Maslonka, Matthew; Nanda, Arjun; Singal, Ashwani K.

In: World Journal of Hepatology, Vol. 8, No. 35, 2016, p. 1584-1592.

Research output: Contribution to journalArticle

Salameh, Habeeb ; Masadeh, Maen ; Al Hanayneh, Muhannad ; Petros, Vincent ; Maslonka, Matthew ; Nanda, Arjun ; Singal, Ashwani K. / PNPLA3 polymorphism increases risk for and severity of chronic hepatitis C liver disease. In: World Journal of Hepatology. 2016 ; Vol. 8, No. 35. pp. 1584-1592.
@article{020f6451f5ee4620a6124e956893f703,
title = "PNPLA3 polymorphism increases risk for and severity of chronic hepatitis C liver disease",
abstract = "AIM To examine the association of PNPLA3 polymorphisms in chronic hepatitis C patients and development of liver disease spectrum. METHODS Literature was searched systematically from PubMed/MEDLINE, EMBASE, and Cochrane search engines for full-length articles written in English that examined PNPLA3 polymorphism in chronic hepatitis C (CHC) patients. Studies evaluating the association of PNPLA3 polymorphism spectrum (fatty liver, steatohepatitis, cirrhosis, and hepatocellular carcinoma) of CHC were included. Pooled data are reported as OR with 95{\%}CI. Our study endpoint was the risk of the entire liver disease spectrum including: Steatosis/fatty liver, cirrhosis, and hepatocellular carcinoma in CHC patients with PNPLA3 polymorphisms. RESULTS Of 380 studies identified, a total of 53 studies were included for full-text review. Nineteen on chronic hepatitis C were eligible for analysis. Pooled ORs for rs738409 GG compared to CC and CG among patients with fatty liver was 2.214 (95{\%}CI: 1.719-2.853). ORs among advanced fibrosis/cirrhosis were 1.762 (95{\%}CI: 1.258-2.468). Similar odds ratios among hepatocellular carcinoma patients were 2.002 (95{\%}CI: 1.519-2.639). Pooled ORs for rs738409 GG and CG compared to CC among patients with fatty liver were 1.750 (95{\%}CI: 1.542-1.986). Pooled ORs for advanced fibrosis/cirrhosis patients were 1.613 (95{\%}CI: 1.211-2.147). All analyses were homogenous and without publication bias except one. The associations were maintained after adjusting for publication bias and heterogeneity. CONCLUSION PNPLA3 polymorphisms have strong association with increased risk and severity of the liver disease spectrum in CHC patients.",
keywords = "Cirrhosis, Hepatitis C virus, Hepatocellular carcinoma, PNPLA3 polymorphism, Rs738409",
author = "Habeeb Salameh and Maen Masadeh and {Al Hanayneh}, Muhannad and Vincent Petros and Matthew Maslonka and Arjun Nanda and Singal, {Ashwani K.}",
year = "2016",
doi = "10.4254/wjh.v8.i35.1584",
language = "English (US)",
volume = "8",
pages = "1584--1592",
journal = "World Journal of Hepatology",
issn = "1948-5182",
publisher = "Baishideng Publishing Group",
number = "35",

}

TY - JOUR

T1 - PNPLA3 polymorphism increases risk for and severity of chronic hepatitis C liver disease

AU - Salameh, Habeeb

AU - Masadeh, Maen

AU - Al Hanayneh, Muhannad

AU - Petros, Vincent

AU - Maslonka, Matthew

AU - Nanda, Arjun

AU - Singal, Ashwani K.

PY - 2016

Y1 - 2016

N2 - AIM To examine the association of PNPLA3 polymorphisms in chronic hepatitis C patients and development of liver disease spectrum. METHODS Literature was searched systematically from PubMed/MEDLINE, EMBASE, and Cochrane search engines for full-length articles written in English that examined PNPLA3 polymorphism in chronic hepatitis C (CHC) patients. Studies evaluating the association of PNPLA3 polymorphism spectrum (fatty liver, steatohepatitis, cirrhosis, and hepatocellular carcinoma) of CHC were included. Pooled data are reported as OR with 95%CI. Our study endpoint was the risk of the entire liver disease spectrum including: Steatosis/fatty liver, cirrhosis, and hepatocellular carcinoma in CHC patients with PNPLA3 polymorphisms. RESULTS Of 380 studies identified, a total of 53 studies were included for full-text review. Nineteen on chronic hepatitis C were eligible for analysis. Pooled ORs for rs738409 GG compared to CC and CG among patients with fatty liver was 2.214 (95%CI: 1.719-2.853). ORs among advanced fibrosis/cirrhosis were 1.762 (95%CI: 1.258-2.468). Similar odds ratios among hepatocellular carcinoma patients were 2.002 (95%CI: 1.519-2.639). Pooled ORs for rs738409 GG and CG compared to CC among patients with fatty liver were 1.750 (95%CI: 1.542-1.986). Pooled ORs for advanced fibrosis/cirrhosis patients were 1.613 (95%CI: 1.211-2.147). All analyses were homogenous and without publication bias except one. The associations were maintained after adjusting for publication bias and heterogeneity. CONCLUSION PNPLA3 polymorphisms have strong association with increased risk and severity of the liver disease spectrum in CHC patients.

AB - AIM To examine the association of PNPLA3 polymorphisms in chronic hepatitis C patients and development of liver disease spectrum. METHODS Literature was searched systematically from PubMed/MEDLINE, EMBASE, and Cochrane search engines for full-length articles written in English that examined PNPLA3 polymorphism in chronic hepatitis C (CHC) patients. Studies evaluating the association of PNPLA3 polymorphism spectrum (fatty liver, steatohepatitis, cirrhosis, and hepatocellular carcinoma) of CHC were included. Pooled data are reported as OR with 95%CI. Our study endpoint was the risk of the entire liver disease spectrum including: Steatosis/fatty liver, cirrhosis, and hepatocellular carcinoma in CHC patients with PNPLA3 polymorphisms. RESULTS Of 380 studies identified, a total of 53 studies were included for full-text review. Nineteen on chronic hepatitis C were eligible for analysis. Pooled ORs for rs738409 GG compared to CC and CG among patients with fatty liver was 2.214 (95%CI: 1.719-2.853). ORs among advanced fibrosis/cirrhosis were 1.762 (95%CI: 1.258-2.468). Similar odds ratios among hepatocellular carcinoma patients were 2.002 (95%CI: 1.519-2.639). Pooled ORs for rs738409 GG and CG compared to CC among patients with fatty liver were 1.750 (95%CI: 1.542-1.986). Pooled ORs for advanced fibrosis/cirrhosis patients were 1.613 (95%CI: 1.211-2.147). All analyses were homogenous and without publication bias except one. The associations were maintained after adjusting for publication bias and heterogeneity. CONCLUSION PNPLA3 polymorphisms have strong association with increased risk and severity of the liver disease spectrum in CHC patients.

KW - Cirrhosis

KW - Hepatitis C virus

KW - Hepatocellular carcinoma

KW - PNPLA3 polymorphism

KW - Rs738409

UR - http://www.scopus.com/inward/record.url?scp=85008168867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008168867&partnerID=8YFLogxK

U2 - 10.4254/wjh.v8.i35.1584

DO - 10.4254/wjh.v8.i35.1584

M3 - Article

AN - SCOPUS:85008168867

VL - 8

SP - 1584

EP - 1592

JO - World Journal of Hepatology

JF - World Journal of Hepatology

SN - 1948-5182

IS - 35

ER -